Argonaut Therapeutics is a spin-out from Oxford University’s Medical Sciences Division focusing on new cancer treatments. The technology is based on original discoveries made in Oxford that characterised abnormal arginine methylation in advanced and metastatic tumours. This established PRMT5 as a drug target and the company generated two distinct series of PRMT5 inhibitors, coupled with proprietary companion diagnostics, which enable a precision medicine approach to treating cancer.
$ 2.5 Millions - $ 5 Millions
Leave a Reply